9
patients), reviewers found reduction mammaplasty improved functional outcomes including
pain, breathing, sleep, and headaches. Additional psychological outcomes noted included
improvements in self-esteem, sexual function, and quality of life. Torresetti et al (2022)
conducted another systematic review to examine the potential association between bilateral
breast reduction and improvement in lung function in women with macromastia.
14,
The review
included 15 studies published from 1974 to 2018 (n range, 1 to 50 patients). The findings
showed that reduction mammaplasty can lead to changes in objective respiratory parameters,
such as spirometric tests or arterial blood gas measurements, but the clinical significance of
these changes was unclear.
Hernanz et al (2016) reported on a descriptive cohort study of 37 consecutive obese patients
who underwent reduction mammoplasty for symptomatic macromastia, along with 37 age-
matched women hospitalized for short-stay surgical procedures.
15
In the preoperative state,
SF-36 physical health component subscore was significantly lower for patients with
symptomatic macromastia (40) than for age-matched controls (53; P<.001), with differences in
5 of the 8 subscales. At 18 months postprocedure, there were no significant differences in any
SF-36 subscores except the body pain subscale between patients who had undergone
reduction mammoplasty and age-matched controls.
Kerrigan et al (2002) published the results of the BRAVO (Breast Reduction: Assessment of
Value and Outcomes) study, a registry of 179 women undergoing reduction mammaplasty.
16
Women were asked to complete quality of life questionnaires and a physical symptom count
both before and after surgery. The physical symptom count focused on the number of
symptoms present that were specific to breast hypertrophy and included upper back pain,
rashes, bra strap grooves, neck pain, shoulder pain, numbness, and arm pain. Also, the weight
and volume of resected tissue were recorded. Results were compared with a control group of
patients with breast hypertrophy, defined as size DD bra cup, and normal-sized breasts, who
were recruited from the general population. The authors proposed that the presence of 2
physical symptoms might be an appropriate cutoff for determining medical necessity for breast
reduction. For example, while 71.6% of the hypertrophic controls reported none or 1 symptom,
only 12.4% of those considered surgical candidates reported none or 1 symptom. This
observation is difficult to evaluate because the study did not report how surgical candidacy was
determined. The authors also reported that none of the traditional criteria for determining
medical necessity for breast reduction surgery (height, weight, body mass index , bra cup size,
or weight of resected breast tissue) had a statistically significant relation with outcome
improvement. The authors concluded that the determination of medical necessity should be
based on patients’ self-reported symptoms rather than more objectively measured criteria (eg,
weight of excised breast tissue).
Adverse Events
Thibaudeau et al (2010), conducted a systematic review to evaluate breastfeeding after
reduction mammaplasty.
17
After a review of literature from 1950 through 2008, reviewers
concluded that reduction mammaplasty does not reduce the ability to breastfeed. In women
who have had reduction mammaplasty, breastfeeding rates were comparable in the first month
postpartum to rates in the general population in North America.
Chen et al (2011) reported on a review of claims data to compare complication rates after
breast surgery in 2,403 obese and ,5597 nonobese patients.
18
Of these patients, breast
reduction was performed in 1,939 (80.7%) in the study group and in ,3569 (63.8%) in the
control group. Obese patients had significantly more claims for complications within 30 days